News about Clinical Trials

Meiji Seika Pharma Initiates Phase I Trial of ME3241 PD-1 Agonist Antibody for Autoimmune Diseases

Meiji Seika Pharma Co., Ltd. has launched a Phase I clinical trial of ME3241, a novel anti-PD-1 agonist antibody developed with Foundation for Biomedical Research and Innovation at Kobe for autoimmune disease treatment.

Clinical Trials | 16/03/2026 | By News Bureau

Immutep Limited Halts Phase III TACTI-004 Trial of Eftilagimod Alfa in Lung Cancer After Futility Review

Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.

Clinical Trials | 16/03/2026 | By News Bureau

EnteroBiotix Completes Patient Enrolment in Phase IIa MAST Trial Evaluating Microbiome Therapy in Stem Cell Transplant Patients

Phase IIa MAST trial of EnteroBiotix’s microbiome therapy EBX-102-02 completes enrolment of 50 patients undergoing allogeneic stem cell transplantation to assess microbiome restoration and transplant outcomes.

Clinical Trials | 12/03/2026 | By News Bureau

IDEAYA Biosciences Enrolls First Patient in Phase I Trial of IDE892 for MTAP-Deleted Solid Tumours

IDEAYA Biosciences has initiated a Phase I clinical trial of IDE892, a PRMT5 inhibitor, for MTAP-deleted cancers including Non-Small Cell Lung Cancer and Pancreatic Cancer.

Clinical Trials | 11/03/2026 | By News Bureau |  160

Aisa Pharma Reports Encouraging Phase II Results for AISA-021 in Systemic Sclerosis-Associated Raynaud's Phenomenon

Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.

Clinical Trials | 10/03/2026 | By News Bureau

Roche Reports Update on PERSEVERA Breast Cancer Trial

Roche reported that the Phase III persevERA study in ER-positive advanced breast cancer did not meet its primary endpoint, though giredestrant plus palbociclib showed numerical improvement and a tolerable safety profile.

Clinical Trials | 09/03/2026 | By News Bureau

Dyne Therapeutics Reports Positive Results from Z-Rostudirsen DMD Study

Dyne Therapeutics reported new 24-month data from the DELIVER trial showing Z-rostudirsen improved cardiopulmonary function in patients with Duchenne Muscular Dystrophy (DMD), building on earlier findings of sustained functional benefits across multiple clinical measures.

Clinical Trials | 09/03/2026 | By News Bureau

HUTCHMED Starts Global Trial of HMPL-A580 for Solid Tumours

HUTCHMED has initiated a global clinical trial of HMPL-A580, a PI3K/PIKK-EGFR ATTC candidate, in patients with solid tumours. The study marks the second clinical programme from its next-generation ATTC platform, targeting both PAM pathway and EGFR signaling to enhance therapeutic synergy.

Clinical Trials | 06/03/2026 | By News Bureau

Intellia Therapeutics Secures U.S. FDA Clearance to Resume Phase III Trial of CRISPR Therapy for ATTR-CM

The FDA lifted the clinical hold on Intellia’s phase III MAGNITUDE trial evaluating CRISPR-based therapy nex-z for transthyretin amyloidosis with cardiomyopathy, enabling the company to resume patient enrollment with enhanced safety measures.

Clinical Trials | 05/03/2026 | By News Bureau

Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial

Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.

Clinical Trials | 02/03/2026 | By News Bureau |  136